Ali Shafiq

Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) project

BACKGROUND Although cardiopulmonary exercise (CPX) testing in patients with heart failure and reduced ejection fraction is well established, there are limited data on the value of CPX variables in patients with HF and preserved ejection fraction (HFpEF). We sought to determine the prognostic value of select CPX measures in patients with HFpEF. METHODS This was a retrospective analysis of patients with HFpEF (ejection fraction ≥ 50%) who performed a CPX test between 1997 and 2010. Selected CPX variables included peak oxygen uptake (VO2), percent predicted maximum oxygen uptake (ppMVO2), minute ventilation to carbon dioxide production slope (VE/VCO2 slope) and exercise oscillatory ventilation (EOV). Separate Cox regression analyses were performed to assess the relationship between each CPX variable and a composite outcome of all-cause mortality or cardiac transplant. RESULTS We identified 173 HFpEF patients (45% women, 58% non-white, age 54 ± 14 years) with complete CPX data. During a median follow-up of 5.2 years, there were 42 deaths and 5 cardiac transplants. The 1-, 3-, and 5-year cumulative event-free survival was 96%, 90%, and 82%, respectively. Based on the Wald statistic from the Cox regression analyses adjusted for age, sex, and β-blockade therapy, ppMVO2 was the strongest predictor of the end point (Wald χ(2) = 15.0, hazard ratio per 10%, P < .001), followed by peak VO2 (Wald χ(2) = 11.8, P = .001). VE/VCO2 slope (Wald χ(2)= 0.4, P = .54) and EOV (Wald χ(2) = 0.15, P = .70) had no significant association to the composite outcome. CONCLUSION These data support the prognostic utility of peak VO2 and ppMVO2 in patients with HFpEF. Additional studies are needed to define optimal cut points to identify low- and high-risk patients.

Association of Smoking Status With Health-Related Outcomes After Percutaneous Coronary Intervention

Background—Patients who smoke at the time of percutaneous coronary intervention (PCI) would ideally have a strong incentive to quit, but most do not. We sought to compare the health status outcomes of those who did and did not quit smoking after PCI with those who were not smoking before PCI. Methods and Results—A cohort of 2765 PCI patients from 10 US centers were categorized into never, past (smoked in the past but had quit before PCI), quitters (smoked at time of PCI but then quit), and persistent smokers. Health status was measured with the disease-specific Seattle Angina Questionnaire and the EuroQol 5 dimensions, adjusted for baseline characteristics. In unadjusted analyses, persistent smokers had worse disease-specific and overall health status when compared with other groups. In fully adjusted analyses, persistent smokers showed significantly worse health-related quality of life when compared with never smokers. Importantly, of those who smoked at the time of PCI, quitters had significantly better adjusted Seattle Angina Questionnaire angina frequency scores (mean difference, 2.73; 95% confidence interval, 0.13–5.33) and trends toward higher disease specific (Seattle Angina Questionnaire quality of life mean difference, 1.97; 95% confidence interval, −1.24 to 5.18), and overall (EuroQol 5 dimension visual analog scale scores mean difference, 2.45; 95% confidence interval, −0.58 to 5.49) quality of life when compared with persistent smokers at 12 months. Conclusions—Smokers at the time of PCI have worse health status at 1 year than those who never smoked, whereas smokers who quit after PCI have less angina at 1 year than those who continue smoking.

The prevalence and management of angina among patients with chronic coronary artery disease across US outpatient cardiology practices: insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study

Although eliminating angina is a primary goal in treating patients with chronic coronary artery disease (CAD), few contemporary data quantify prevalence and severity of angina across US cardiology practices. The authors hypothesized that angina among outpatients with CAD managed by US cardiologists is low and its prevalence varies by site. Among 25 US outpatient cardiology clinics enrolled in the American College of Cardiology Practice Innovation and Clinical Excellence (PINNACLE) registry, we prospectively recruited a consecutive sample of patients with chronic CAD over a 1‐ to 2‐week period at each site between April 2013 and July 2015, irrespective of the reason for their appointment. Eligible patients had documented history of CAD (prior acute coronary syndrome, prior coronary revascularization procedure, or diagnosis of stable angina) and ≥1 prior office visit at the practice site. Angina was assessed directly from patients using the Seattle Angina Questionnaire Angina Frequency score. Among 1257 patients from 25 sites, 7.6% (n = 96) reported daily/weekly, 25.1% (n = 315) monthly, and 67.3% (n = 846) no angina. The proportion of patients with daily/weekly angina at each site ranged from 2.0% to 24.0%, but just over half (56.3%) were on ≥2 antianginal medications, with wide variability across sites (0%–100%). One‐third of outpatients with chronic CAD managed by cardiologists report having angina in the prior month, and 7.6% have frequent symptoms. Among those with frequent angina, just over half were on ≥2 antianginal medications, with wide variability across sites. These findings suggest an opportunity to improve symptom control.

Beyond restenosis: Patients' preference for drug eluting or bare metal stents

To assess patients’ perspective about factors associated with stent choice.

The Association Between Complementary and Alternative Medicine and Health Status Following Acute Myocardial Infarction

Complementary and alternative medicines (CAM) are commonly used in patients with cardiovascular disease. Although there is lack of evidence regarding the benefit of CAM on cardiovascular morbidity and mortality, health‐status benefits could justify CAM use.

PREDICTING THE LIKELIHOOD FOR CORONARY ARTERY BYPASS GRAFTING IN NON ST ELEVATION MYOCARDIAL INFARCTION PATIENTS

Current ACC/AHA guidelines recommend dual antiplatelet therapy (DAPT) on presentation in patients with non ST elevation myocardial infarction (NSTEMI). This practice, however, can complicate coronary artery bypass (CABG) procedures, required in 8% to 25% of NSTEMI patients, and lead to delays in

Challenges with Percent Predicted Maximum VO2 in Patients with Heart Failure

Purpose This study aimed to describe the influence of different equations to predict maximal oxygen uptake (MV˙O2) on the percent predicted MV˙O2 (ppMV˙O2) and the resultant categorization of patients with heart failure with reduced ejection fraction into high or low risk. Methods In this retrospective cohort study, ppMV˙O2 was calculated using six different equations to predict MV˙O2 among 1168 patients with heart failure with reduced ejection fraction (33% women). Repeated-measures ANOVA was used to compare within-subject differences in mean ppMV˙O2 between the prediction equations. Cochrane’s Q test was used to compare the within-subject difference in the proportion of patients with ppMV˙O2 of <50% (high risk) and ≥75% (low risk) between the prediction equations. Results The ppMV˙O2 varied significantly (P < 0.001) between the MV˙O2 prediction equations, with mean (10th, 90th percentile) ppMV˙O2 ranging from 39% (25%, 54%) to 60% (39%, 83%) in men and 37% (24%, 49%) to 70% (47%, 94%) in women. Significant variation (P < 0.001) was also observed between prediction equations for the proportion of patients with ppMV˙O2 of <50% and ≥75% in men and women. Conclusions Statistically significant and clinically meaningful variations in the ppMV˙O2 are observed on the basis of the reference equation used to predict MV˙O2. Future writing committees should specify the preferred reference equation when identifying a ppMV˙O2 criterion in guideline statements.

ASSOCIATION OF SMOKING STATUS WITH HEALTH-RELATED OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION

Patients who smoke at the time of percutaneous coronary intervention (PCI) would ideally have a strong incentive to quit, but most do not. Showing how smoking cessation may be associated with the benefits of PCI, in terms of symptoms, function and quality of life, might provide a stronger incentive